181 results about "Neurologic disease" patented technology

Implementations described and claimed herein provide systems and methods for a cloud-based seizure management platform for personalized management of seizures while providing assured connectedness across multiple stakeholders. The systems and methods address the needs of a patient in the area of seizure management, through such functionalities as seizure detection, seizure histories and other health-related data management, stakeholder connectedness, tachyphylaxis detection, drug titration guidance, and / or treatment aggressiveness management. The system provides for access for multiple parties, including allowing neurologists and / or caregivers to monitor progression of neurological conditions on a continuous basis while at home or otherwise remote from the patient. The unique methodology of the seizure management system includes wearable technologies coupled with artificial intelligence, machine-learning algorithms, and data modeling techniques to enable personalization of care.

The present disclosure provides compounds, compositions, and methods for treating or preventing neurological disorders in a patient. The disclosed methods include administration to a subject suffering from a neurological disorder of a compound disclosed herein.

The present invention relates to a compound of formula (I). It also relates to a pharmaceutical composition comprising at least one compound of formula (I) and at least one pharmaceutically acceptable support. Finally, it relates to the use of such a compound as a medicine, preferably in the treatment of a nervous and / or respiratory failure due to intoxication with at least one organophosphorous nerve agent; in the treatment of neurological diseases such as Alzheimer's disease; and / or in the treatment of cancer.

The present invention relates to a technology for developing a next-generation extracellular vesicle-based therapeutic agent and, more specifically, to a composition comprising three-dimensional stem cell-derived exosomes and neural crest cell-derived exosomes for alleviating neurological diseases. When extracellular vesicles of the present invention are administered in combination, progression of neuropathy can be effectively delayed or treated.

To provide a method of treating an inflammatory neurological disease or condition that can result in destruction or degeneration of axons or myelin.SOLUTION: Provided is a combination comprising a) a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof; and b) one or more drugs selected from the group consisting of I) a compound of a particular formula or a pharmaceutically or veterinarily acceptable salt thereof; ii) a sphingosine-1-phosphate receptor inhibitor (S1PR modulator); and iii) a signal transducer and activator of transcription 3 (STAT3) inhibitor.SELECTED DRAWING: None

The present invention relates to peptide conjugates that comprise a plant-derived oligopeptide capable of crossing the blood-brain barrier (BBB) and a therapeutic or diagnostic agent. The BBB-penetrating oligopeptide is an oligopeptide according to Formula I, Asp–R2–Gly–Leu–R5–R6–R7–Leu–Gly–R10–R11–R12, wherein R2 represents Arg, Lys, Cyt, D-Arg or Orn; R5 represents Phe, Arg, Lys, His, Trp, Tyr, D-Tyr, D-Phe, Orn, 4-aminophenylalanine or 3-phenylpropionate; R6 represents Pro, Leu, Glu or Lys; R7 represents Phe or Trp; R10, R11 and R12 each independently represent Lys, Arg or Orn; or an oligopeptide according to Formula II, Glu–R2'–R3'–Gly–R5'–R6'–Glu–R8'–R9'–R10'–Glu–R12'–Leu–Pro–Gly, wherein R2', R3', R8', R10' and R12' each independently represent Lys, Arg or Orn; R5' represents Phe, Ile, Arg, Lys, His, Trp, Tyr, D-Tyr, D-Phe, 4-aminophenylalanine, or 3-phenylpropionate; R6' represents Met, Leu, Ile, Asn, norleucin, D-norleucin, seleno- methionine or D / L-2-hydroxy-(4-methylseleno)butanoic acid; and R9' represents Leu or Ile. The conjugates comprising a BBB-penetrating oligopeptide compound and a therapeutic agent can be used in treatments for diseases of the central nervous system (CNS). Furthermore, conjugates with a BBB-penetrating oligopeptide compound and a diagnostic agent can be used in both in vivo and in vitro diagnostic methods.

The present invention relates to inhalable formulations, and kits and methods suitable for the preparation of such inhalable formulations. The inhalable formulations comprise a freebase of a deuterium-substituted dimethyltryptamine compound. The inhalable formulations also comprise a biocompatible excipient. Such formulations are suitable for inhalation and have uses in the treatment of psychiatric or neurological disorders. Deuterium-substituted dimethyltryptamine compounds may be metabolised more slowly than their protio analogues, allowing for a longer lasting therapeutic effect.

Disclosed herein is a method of safely treating a nervous system condition with a combination of dextromethorphan and bupropion. This method is intended for patients having a neurological condition or a psychiatric condition, such as major depressive disorder, and a CYP2D6 poor metabolizer genotype or a CYP2D6 poor metabolizer phenotype.

Methods and compositions are provided for treating or preventing a neurological disease or disorder using an inhibitor of Glyoxalase 1 (GLO1). In some embodiments, the inhibitor is a small molecule. In certain embodiments, the disease or disorder is a sleep disorder, a mood disorder such as depression, epilepsy, an anxiety disorder, substance abuse, substance dependence or substance such as an alcohol withdrawal syndrome.

The present invention is directed to dihydroquinazoline, -benzothiazine and -benzoxazine derivatives, advantageously for use in the prevention or treatment of neurological, psychiatric and sleep disorders and diseases in which central orexin neurotransmission is impaired or in which central and peripheral orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds for use in the prevention and / or treatment of neurological disorders and diseases. The present invention is also directed to dihydroquinazoline, -benzothiazine and -benzoxazine derivatives and the use of these compounds as medicaments.

Disclosed herein are salts and solid forms of MDMA, (R)-MDMA, (S)-MDMA, MDE, S-MDE, R-MDE, MDAI, MBDB, S-MBDB, R-MBDB, MEAI, and 5,6-Dimethoxy-2-aminoindane, including salts, solid forms of the compound and salts thereof, as well as polymorphs of solid forms. The solid forms disclosed herein may have improved properties, such as improved physical, chemical, and / or pharmacokinetic properties. Also disclosed are methods for making the salts and solid forms and methods for administering the same. The disclosed salt and solid forms of MDMA, (R)-MDMA, (S)-MDMA, MDE, S-MDE, R-MDE, MDAI, MBDB, S-MBDB, R-MBDB, MEAI, and 5,6-Dimethoxy-2-aminoindane may be useful for treating neurological disease and / or a psychiatric disorder in a subject.

The application discloses a neural system disease intraoperative monitoring system based on a large model, relates to the technical field of medical information processing, and comprises a synchronous acquisition module, a mapping construction module, a consistency evaluation module, a semantic normalization module and an attribution decision module. The system synchronously acquires double-channel vocal cord electromyography signals and stimulation events, intercepts a response segment and calculates a dominant side symbol; the consistency score of normal and reverse syntax is counted in a recording window, and channel side reversal caused by tracheal intubation rotation is actively identified; accordingly, semantic normalization processing of channel exchange or retention is performed, and the underlying anatomical mapping is corrected; finally, the large model reasons the normalized signal, accurately distinguishes real physiological damage from device measurement artifacts, and maps and outputs action instructions. The application eliminates semantic pollution caused by side error to the large model from the root, and greatly improves the accuracy of intraoperative intelligent monitoring.

Disclosed are neuronal nitric oxide synthase (nNOS) inhibitors and methods of using the same in treating a disease or disorder associated with nNOS activity, such as a neurological disease or disorder, or melanoma.

MEDICAL DEVICE TO DETECT EMOTIONS OF A NEUROLOGIC PATIENT

Fused heteroaryl compounds and compositions useful for preventing and / or treating a disease or condition related to aberrant function of voltage-gated sodium ion channels, e.g., an abnormal, delayed / persistent sodium current. Treatment methods for a disease or condition related to aberrant function of sodium ion channels are also provided herein, including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders.

Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein Ring A, Ring B, R1, R2, R3, R12, and L are as defined herein. The compounds are antagonists of the resistant (R-type) voltage-gated calcium ion channel Cav 2.3. Also disclosed are pharmaceutical compositions comprising the compounds; and the compounds for use in the treatment of diseases modulated Cav 2.3, including epilepsy, neurodegenerative conditions such as Parkinson's disease, focal, drug-resistant forms of epilepsy, and other neurological disorders such as developmental and epileptic encephalopathies and Phelan-McDermid and Fragile X syndromes.

This invention discloses an MDGA2-targeting polypeptide and its applications, which consists of 8-55 consecutive amino acids of the RPS23RG1 protein and contains QHNSX1CMR, where X1 is F or L. The MDGA2-targeting polypeptide and fusion protein of this invention can significantly inhibit the lysosomal degradation of MDGA2, thereby increasing MDGA2 levels. Therefore, it can be used to treat diseases associated with low MDGA2 activity (such as autism and other neurological disorders and gastric cancer), and has significant clinical value.

In various aspects and embodiments provided are compositions and methods for identifying patients in need of improving cognition and / or treating a neurodegenerative disease in a patient and treating such patient. More specifically, the disclosure in some embodiments includes administration of a β-AR agonist and a peripherally acting β-blocker (PABRA) to a patient in need thereof.

Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions / disorders / diseases due to mutations or dysregulation of the Wnt pathway and / or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

To provide an image-guided variable spot light stimulation electrophysiology device applicable to structural / functional imaging and evaluation.SOLUTION: To provide an application of a device for performing image-guided functional assessment based on variable spot light stimulation of a light-activated biological sample to determine changes in functional health during disease progression and treatment. More specifically, the invention relates to the application of the device in the diagnosis of vision and neurological disorders.SELECTED DRAWING: Figure 1

Disclosed are polypeptides useful in the treatment of diseases associated with pathogenic genomic repetitive sequences, such as neurological diseases. Nucleic acid molecules and vectors encoding such polypeptides are also disclosed. Also disclosed are therapeutic uses and methods of treating such diseases; in particular, the present invention relates to therapeutic uses and methods for the treatment of Friedel's Ataxia (FRDA). Also disclosed are methods and related peptides and nucleic acids for active, long-term delivery of therapeutic molecules to target cells in vivo or in vitro.

Systems and methods in accordance with embodiments of the present disclosure include the creation and utilization of synthetic eye and head movement datasets that can be used as digital biomarkers for the screening, diagnosis or monitoring of neurologic diseases, including rare neurologic conditions. The synthetic datasets can be used to train deep learning models that can identify and phenotype neurologic diseases based on distinct eye movement patterns. The system and method create synthetic eye movement datasets using generative Al techniques. A pose-guided video generation framework is utilized to produce synthetic eye movement videos. A latent video diffusion mechanism translates segmented mask inputs — simplified representations of eye movements — into realistic visual sequences that mimic real eye movements associated with specific neurologic diseases.

A supplement, and a method of treatment utilizing the supplement to elicit positive responses in a patient with neurological conditions is disclosed. The supplement comprises four components: N-acetylcysteine, glycine, choline, and biotin. In the preferred embodiment for treating adult patients, the effective supplement daily dosage comprises at least 1500 mg of glycine, 1500 mg of N-acetylcysteine, 1000 mg of choline, and 1000 μg of biotin. In another embodiment for treating pediatric patients, the supplement may comprise an effective supplement daily dosage of at least 500 mg of glycine, 500 mg of N-acetylcysteine, 250 mg of choline, and 250 μg of biotin. In a method embodiment, regular daily dosages of a supplement comprising over 1 g total of the four components are administered, resulting in improved outcomes among patients with cognitive impediments.

Materials and methods are provided herein for detecting the presence of an autoantibody specific for PDE10A to identify the mammal as having an autoimmune neurological disorder as well as methods and materials for treating an autoimmune neurological disorder. Materials and methods also are provided herein for treating cancer and / or neurological autoimmunity in a mammal using an immune checkpoint inhibitor and detecting the presence of an autoantibody specific for PDE10A to monitor for the development of neurologic complications in the mammal.

Disclosed are compositions and / or methods of use of the compositions for patients with neuronal diseases such as AD, Parkinson's, Huntington's, multiple sclerosis, and ALS. In certain embodiments flavonoids alone, or in a pharmaceutical preparation, are administered through the nasal olfactory route. In certain embodiments the flavonoid is apigenin and the neural disease is Alzheimer's. In some embodiments a porosome complex is administered for reconstitution into a neural cell. In certain embodiments, a co-administered blood-brain barrier traversing peptide is configured as a mimic of a domain of ATP 1 A3 and / or Tubulin.

This invention belongs to the field of pharmaceutical technology, specifically relating to a novel tannin derivative isolated for the first time from *Cotinus coggygria*, its preparation method, and its pharmaceutical uses. This compound exhibits significant neuroprotective activity, counteracting glutamate-induced excitotoxic damage and inhibiting TNF-α-mediated neuroinflammatory responses. It can be used to prepare drugs for the prevention or treatment of neurological diseases involving excitotoxicity and / or neuroinflammatory disorders. Formula (I)

The present invention relates to splice variants of the CERT1 protein that act as biomarkers for TDP-43 pathology, particularly motor neuron diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD), as well as other neurological diseases such as Alzheimer's disease. In particular, the present invention relates to a method for identifying splice variants of CERT1 comprising cryptic peptide sequences, as well as related methods for identifying TDP-43 pathology and / or TDP-43 dysfunction in a subject, and a method for predicting the likelihood of successful treatment. Antibodies that bind to CERT1 splice variants and kits comprising said antibodies are also claimed.